{"id":4622,"date":"2025-03-31T18:12:14","date_gmt":"2025-03-31T18:12:14","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/pethidine-hydrochloride-txt\/"},"modified":"2025-03-31T18:12:14","modified_gmt":"2025-03-31T18:12:14","slug":"pethidine-hydrochloride-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/pethidine-hydrochloride-txt\/","title":{"rendered":"pethidine hydrochloride.txt"},"content":{"rendered":"

CLINICAL USE <\/H3>
\nOpiate analgesia

DOSE IN NORMAL RENAL FUNCTION <\/H3>IV: 25\u201350 mg every 4 hoursOral: 50\u2013150 mg every 4 hoursS\/C, IM: 25\u2013100 mg every 4 hours

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :283.8<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :60\u201380<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 5<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :4.17<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :3\u20136\/7\u201332

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Use small doses \u2013 increase dosing interval to 6 hours and decrease dose by 25%
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Avoid if possible. If not, use small doses: increase dosing interval to 8 hours and decrease dose by 50%

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in GFR <10 mL\/min <\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as in GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unlikely dialysability. Dose as in GFR 10 to 20 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Anti-arrhythmics: delayed absorption of mexiletine\n
  • Antidepressants: possible CNS excitation or depression with MAOIs and moclobemide \u2013 avoid concomitant use; possibly increased serotonergic effects with duloxetine; increased sedative effects with tricyclics\n
  • Antipsychotics: enhanced sedative and hypotensive effect\n
  • Antivirals: concentration reduced by ritonavir but concentration of toxic pethidine metabolite increased \u2013 avoid concomitant use\n
  • Dopaminergics: risk of CNS toxicity with rasagiline \u2013 avoid concomitant use; hyperpyrexia and CNS toxicity reported with selegiline \u2013 avoid concomitant useSodium oxybate: enhanced effect of sodium oxybate \u2013 avoid concomitant use

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>IV, oral, SC, IM

    Rate of Administration <\/H4>IV: Bolus 3\u20134 minutes

    Comments<\/H4>\u2013

    OTHER INFORMATION <\/H4>Risk of CNS and respiratory depression or convulsions, particularly in ERF patients receiving regular doses, due to accumulation of active metabolite, norpethidine. Norpethidine levels can be measured
    \n","protected":false},"excerpt":{"rendered":"

    CLINICAL USE Opiate analgesia DOSE IN NORMAL RENAL FUNCTION IV:<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4622","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4622","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4622"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4622\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4622"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4622"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4622"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}